$17.65
+1.73 (+10.87%)
VERX News5 articles
Vertex Raises Outlook as CF Dominates, Non-CF Push Faces Steep Climb
Vertex Pharmaceuticals raised its 2026 outlook after strong Q2, but non-CF drugs Casgevy and Journavx face a 53% H2 growth hurdle.
Biotech Sector Hit by $15B Loss as Vertex, Ionis Stumble
Vertex and Ionis shares slumped after setbacks, erasing $14.8B in market cap. Crinetics, BridgeBio, and Vera gained $6.1B combined.
Vertex's $10B Cash Deal Narrows Crinetics' Merger Spread
Crinetics shares traded at $83.60 premarket, just 1.7% below Vertex's $85 cash offer, as the $10 billion deal shifts focus from biotech fundamentals to merger arbitrage.
Vertex Shares Slide on Updated Safety Warnings for CF Drugs
Vertex Pharmaceuticals shares declined 4.6% to $433.07 following updated U.S. safety labels for its cystic fibrosis drugs citing serious neuropsychiatric events. The company maintains its 2026 revenue outlook remains heavily dependent on CF treatments.
Vertex Shares Surge on Analyst Upgrade, Pipeline Expansion in Focus
Vertex Pharmaceuticals shares climbed 5.7% following an upgrade from Oppenheimer, driven by its 2026 revenue outlook and expanding pipeline in gene-editing, pain, and kidney therapies.